STUDY SEARCH RESULTS

1 study found for your search request:  2140-006

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants with Agg...
Condition: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
Minimum Age: 18 years, Maximum Age: N/A
Gender: All
Study ID: NCT05458297
Status: Recruiting
Has Enrolling Locations in US or Canada




Copyright © 2024 · Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved. · This site is intended only for residents of the United States.
Cookie Preferences  Privacy  Terms of Use  U.S. Corporate Site